205 completed, 72 terminated, 43 recruiting, 39 unknown. 285 Phase 2, 148 Phase 1, 39 Phase 3, 7 Early Phase 1, 5 Not applicable.
Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 40 | 2026-12-31 | 2026-10-28 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Navlimetostat, Daraxonrasib, Temozolomide - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 254 | 2026-07-27 | 2026-11-04 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| Window of Opportunity in Preserving Laryngeal Function Trial Toripalimab, Carboplatin, Cisplatin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Matthew Spector | 87 | 2026-04-06 | 2026-10-16 |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
| BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 43 | 2025-12-12 | 2026-10-02 |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2025-10-29 | 2025-11-10 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 470 | 2025-10-23 | 2026-06-03 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC Cisplatin, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 318 | 2025-06-13 | 2026-09-21 |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors ERAS-0015, ERAS-0015 in combination - Metastatic Solid Tumors | Phase 1 | Recruiting | Erasca, Inc. | 600 | 2025-06-05 | 2026-09-01 |
| A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) Pembrolizumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 90 | 2025-03-30 | 2026-10-16 |
| Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer sintilimab, nab-paclitaxel, gemcitabine - Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 50 | 2025-03-20 | 2025-01-22 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-10-13 |
| Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, TheraBionic P1 - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-02-28 | 2026-08-10 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy Abraxane, Nedaplatin - Hepatic Artery Infusion, Liver Metastasis of Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 30 | 2025-02-01 | 2025-12-16 |
Showing 20 of 418. Sign in to see all of them.
Pancreatic Neoplasms (115) · Breast Neoplasms (77) · Carcinoma, Non-Small-Cell Lung (40) · Neoplasms (33) · Neoplasm Metastasis (32) · Triple Negative Breast Neoplasms (27) · Lung Neoplasms (24) · Ovarian Neoplasms (15) · Adenocarcinoma (14) · Squamous Cell Carcinoma of Head and Neck (14) · Melanoma (12) · Recurrence (12) · Head and Neck Neoplasms (10) · Sarcoma (10) · Cholangiocarcinoma (9)
Celgene (18) · M.D. Anderson Cancer Center (17) · Washington University School of Medicine (13) · UNC Lineberger Comprehensive Cancer Center (9) · National Cancer Institute (NCI) (8) · Mayo Clinic (7) · SCRI Development Innovations, LLC (7) · Abramson Cancer Center at Penn Medicine (6) · Columbia University (6) · Merck Sharp & Dohme LLC (6) · OHSU Knight Cancer Institute (6) · Chinese PLA General Hospital (5) · City of Hope Medical Center (5) · Emory University (5) · Fudan University (5)
United States (303) · China (41) · Spain (41) · Italy (37) · Germany (36) · Canada (32) · France (29) · Australia (26) · United Kingdom (24) · South Korea (21) · Taiwan (19) · Belgium (16) · Japan (16) · Austria (15) · Poland (13)
Jared Weiss, MD (5) · Douglas Adkins, M.D. (3) · Jenny C Chang, MD (3) · Peter O'Dwyer, MD (3) · Charles D Lopez (2) · Douglas R Adkins, M.D. (2) · Dung Le, MD (2) · Hak Choy, MD (2) · Hemant Kocher, Professor (2) · Ileana Elias, M.D. (2) · John Hainsworth, MD (2)
PMID 31401903, PMID 28797458, PMID 30998813, PMID 34252375, PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 18565862, PMID 19426218, PMID 19706807, PMID 20164695, PMID 20516428, PMID 20530281, PMID 20585851, PMID 20625120, PMID 20636820, PMID 20658263, PMID 20705560, PMID 21359953, PMID 21976055, PMID 22162229, PMID 22307213, PMID 22960352, PMID 23659317, PMID 23706985, PMID 24013936, PMID 24131140, PMID 24318901, PMID 24327518, PMID 24422706, PMID 24703985, PMID 24953566, PMID 25398812, PMID 25579459, PMID 25601342, PMID 25616430, PMID 25638248, PMID 25845992, PMID 26056183, PMID 26372701, PMID 26445094, PMID 26606200, PMID 26655559, PMID 26698868, PMID 26802153, PMID 26802160
2015 (4), 2016 (4), 2023 (4), U10CA180820 (4), 2019 (3), P30CA015083 (3), P30CA033572 (3), P30CA138292 (3), U10CA180868 (3), U10CA180888 (3), 2014 (2), 2025 (2), P30CA068485 (2), P50CA196510 (2), U10CA027469 (2)